Syros to Participate in TD Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. Management will also be available for one-on-one meetings. Details are as follows:

TD Cowen 44th Annual Health Care Conference

Date: Tuesday, March 5
Panel Title: Novel Oncology Targets
Panel Time: 9:10 a.m. ET
Location: Boston Marriott Copley Place, Boston, MA

A live webcast of the panel discussion will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the live event.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227887206/en/

Syros Contact
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
[email protected]

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Source: Syros Pharmaceuticals

You May Also Be Interested In

• New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026
• kiero Launches in the U.S. Following Rapid Growth in Mexico
• XRP ETF Demand Builds as IceBull Keeps Stage 1 Open for Buyers Searching for the Best Crypto to Buy Now